BACKGROUND: The current standard treatment for patients infected with hepatitis C virus (HCV) of genotype 2 is the combination of peginterferon (PEG-IFN) plus ribavirin (RBV) for 24 weeks. AIMS: We assessed the sustained virological response (SVR) rates in HCV genotype 2-infected Japanese patients in relation to the duration of treatment. METHODS: Between 2006 and 2009, among 147 patients with HCV genotype 2-infection in Chiba Prefecture, 138 consecutive patients were finally enrolled. Twenty-one, 97 and 20 patients were treated with PEG-IFN-alfa 2b plus RBV for 16, 24 and 48 weeks, respectively. Epidemiological data and treatment outcomes were retrospectively evaluated. HCV RNA was measured with COBAS AMPLICOR HCV Monitor Test v. 2.0. RESULTS: The overall SVR rate was 82.6% (114 of 138): treatment-naïve patients, 86.4% (89 of 103); patients with history of previous treatment, 71.4% (25 of 35). Patients treated for 16, 24 and 48 weeks obtained SVR rates of 66.6% (14 of 21), 86.5% (84 of 97) and 80.0 (16 of 20), respectively. CONCLUSIONS: The SVR rates of PEG-IFN-alfa 2b plus RBV in Japanese patients were similar to those in previous studies. Combination treatment for 24 weeks for some patients infected with HCV genotype 2 may be superior to that for 16 weeks. More precise patient selection will be needed to shorten the combination treatment.
BACKGROUND: The current standard treatment for patients infected with hepatitis C virus (HCV) of genotype 2 is the combination of peginterferon (PEG-IFN) plus ribavirin (RBV) for 24 weeks. AIMS: We assessed the sustained virological response (SVR) rates in HCV genotype 2-infected Japanese patients in relation to the duration of treatment. METHODS: Between 2006 and 2009, among 147 patients with HCV genotype 2-infection in Chiba Prefecture, 138 consecutive patients were finally enrolled. Twenty-one, 97 and 20 patients were treated with PEG-IFN-alfa 2b plus RBV for 16, 24 and 48 weeks, respectively. Epidemiological data and treatment outcomes were retrospectively evaluated. HCV RNA was measured with COBAS AMPLICOR HCV Monitor Test v. 2.0. RESULTS: The overall SVR rate was 82.6% (114 of 138): treatment-naïve patients, 86.4% (89 of 103); patients with history of previous treatment, 71.4% (25 of 35). Patients treated for 16, 24 and 48 weeks obtained SVR rates of 66.6% (14 of 21), 86.5% (84 of 97) and 80.0 (16 of 20), respectively. CONCLUSIONS: The SVR rates of PEG-IFN-alfa 2b plus RBV in Japanese patients were similar to those in previous studies. Combination treatment for 24 weeks for some patients infected with HCV genotype 2 may be superior to that for 16 weeks. More precise patient selection will be needed to shorten the combination treatment.
Authors: Michael Manns; Stefan Zeuzem; Ajit Sood; Yoav Lurie; Markus Cornberg; Hartwig Klinker; Peter Buggisch; Martin Rössle; Holger Hinrichsen; Ismail Merican; Yaron Ilan; Stefan Mauss; Saif Abu-Mouch; Andryes Horban; Thomas H Müller; Christoph Welsch; Rongdean Chen; Rab Faruqi; Lisa D Pedicone; Heiner Wedemeyer Journal: J Hepatol Date: 2011-01-13 Impact factor: 25.083
Authors: T Kanda; F Imazeki; Y Yonemitsu; S Mikami; N Takada; T Nishino; M Takashi; A Tsubota; K Kato; N Sugiura; A Tawada; S Wu; T Tanaka; S Nakamoto; R Mikata; M Tada; T Chiba; T Kurihara; M Arai; K Fujiwara; F Kanai; O Yokosuka Journal: J Viral Hepat Date: 2010-12-03 Impact factor: 3.728
Authors: Martin Lagging; Rune Wejstål; Ingrid Uhnoo; Barbro Gerdén; Björn Fischler; Styrbjörn Friman; Filip Josephson; Olle Karlström; Per Sangfelt; Robert Schvarz; Ola Weiland Journal: Scand J Infect Dis Date: 2009
Authors: John G McHutchison; Michael Manns; Keyur Patel; Thierry Poynard; Karen L Lindsay; Christian Trepo; Jules Dienstag; William M Lee; Carmen Mak; Jean-Jacques Garaud; Janice K Albrecht Journal: Gastroenterology Date: 2002-10 Impact factor: 22.682
Authors: Masao Omata; Tatsuo Kanda; Osamu Yokosuka; Darrell Crawford; Mamun Al-Mahtab; Lai Wei; Alaaeldin Ibrahim; George K K Lau; Barjesh C Sharma; Saeed S Hamid; Wan-Long Chuang; A Kadir Dokmeci Journal: Hepatol Int Date: 2015-05-05 Impact factor: 9.029